No Data
Zhixiang Jintai (688443.SH): GR2001 injection launched Phase III clinical trial.
On August 14th, Gelunhui reported that Zhixiang Jintai (688443.SH) had completed communication with the Center for Drug Evaluation of the National Medical Products Administration (CDE) EOP2 (Phase II clinical trial completed/Phase III clinical trial started) on the conduct of a randomized, double-blind, tetanus immunoglobulin-controlled, multicenter Phase III clinical trial of the efficacy and safety of the evaluation of muscle injection GR2001 injection in suspected tetanus exposed persons, and the company will formally launch the Phase III clinical trial.
Haitong Int'l: Immune therapy has a broad market space, and the clinical value of TCE dual-antibodies is prominent.
With the development and maturity of TCE dual antibody technology, more domestic enterprises will choose to layout TCE dual antibody in order to enter the race track of solid tumors and self-immunity areas. TCE dual antibody has the potential to become the next investment trend in the field of immunotherapy.
Zhixiang Jintai (688443.SH): GR1803 injection has been included in the list of breakthrough therapeutic varieties.
On August 12th, Gelun Hui announced that its product GR1803 injection has been included in the list of breakthrough therapeutic products by the Drug Evaluation Center of China's National Medical Products Administration and the publication has been completed. GR1803 injection is a bi-specific antibody drug independently developed by the company, targeting BCMA and CD3. Its registration classification is Class 1 biological product for therapeutic use. GR1803 injection is a bi-specific antibody molecule based on co-constructed light chains. Its structure is highly similar to that of normal monoclonal antibody molecules, which not only facilitates the development of its preparation process but also reduces the structural differences that may cause
Zhi Xiang Jintai (688443.SH): GR1802 injection starts phase III clinical trial for chronic sinusitis with nasal polyps indication.
On August 6th, Gelonghui reported that Zhixiang Jintai (688443.SH) announced the launch of a randomized, double-blind, placebo-controlled, multicenter phase III clinical trial to evaluate the effectiveness, safety and immunogenicity of GR1802 injection in patients with chronic sinusitis and nasal polyps. The company completed a meeting with the Center for Drug Evaluation (CDE) EOP2 (phase II clinical trial completion/phase III clinical trial initiation) of the State Administration for Drug Supervision and Administration for drug evaluation, and it will officially launch the phase III clinical trial. GR1802 injection is a recombinant human anti-IL- drug independently developed by the company.
Institutions Along With Private Equity Firms Who Hold Considerable Shares InChongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) Come Under Pressure; Lose 5.6% of Holdings Value
Zhixiang Jintai (688443.SH): the preventive tetanus drug "GR2001 injection" has been included in the list of breakthrough therapies.
Zhixiang Jintai (688443.SH) announced that the company's pharmaceutical, GR2001 injection, has been approved by the National Medical Products Administration of China.
No Data
